Immunogenicity of Pseudomonas aeruginosa recombinant b-type fagellin as a vaccine candidate: Protective efficacy in a murine burn wound sepsis model

Kramer, 2006, How long do nosocomial pathogens persist on inanimate surfaces? A systematic review, BMC Infect Dis, 6, 130, 10.1186/1471-2334-6-130 Lyczak, 2000, Establishment of Pseudomonas aeruginosa infection: lessons from a versatile opportunist, Microbes Infect, 2, 1051, 10.1016/S1286-4579(00)01259-4 Church, 2006, Burn wound infections, Clin Microbiol Rev, 19, 403, 10.1128/CMR.19.2.403-434.2006 Nathwani, 2014, Clinical and economic consequences of hospital-acquired resistant and multidrug-resistant Pseudomonas aeruginosa infections: a systematic review and meta-analysis, Antimicrob Resist Infect Control, 3, 32, 10.1186/2047-2994-3-32 Collins, 1983, Anti-Pseudomonas aeruginosa activity of an intravenous human IgG preparation in burned mice, J Trauma, 23, 530, 10.1097/00005373-198306000-00015 Cryz, 1983, Protection against Pseudomonas aeruginosa infection in a murine burn wound sepsis model by passive transfer of antitoxin A, antielastase, and antilipopolysaccharide, Infect Immun, 39, 1072, 10.1128/IAI.39.3.1072-1079.1983 Nance, 1970, Treatment of experimental burn wound sepsis by postburn immunization with polyvalent Pseudomonas antigen, Surgery, 68, 248 Ha, 1999, Expression of the soxR gene of Pseudomonas aeruginosa is inducible during infection of burn wounds in mice and is required to cause efficient bacteremia, Infect Immun, 67, 5324, 10.1128/IAI.67.10.5324-5331.1999 Allison, 1985, Electrophoretic separation and molecular weight characterization of Pseudomonas aeruginosa H-antigen flagellins, Infect Immun, 49, 770, 10.1128/IAI.49.3.770-774.1985 Haiko, 2013, The role of the bacterial flagellum in adhesion and virulence, Biology (Basel), 2, 1242 Drake, 1987, Protection against Pseudomonas aeruginosa infection by passive transfer of anti-flagellar serum, Can J Microbiol, 33, 755, 10.1139/m87-130 Ochi, 1991, Inhibitory activity on bacterial motility and in vivo protective activity of human monoclonal antibodies against flagella of Pseudomonas aeruginosa, Infect Immun, 59, 550, 10.1128/IAI.59.2.550-554.1991 Rosok, 1990, Generation and characterization of murine antiflagellum monoclonal antibodies that are protective against lethal challenge with Pseudomonas aeruginosa, Infect Immun, 58, 3819, 10.1128/IAI.58.12.3819-3828.1990 Korpi, 2015, Active immunization with recombinant PilA protein protects Against Pseudomonas aeruginosa infection in a mouse burn wound model, J Microbiol Biotechnol Faezi, 2014, Protective efficacy of Pseudomonas aeruginosa type-A flagellin in the murine burn wound model of infection, APMIS, 122, 115, 10.1111/apm.12101 Behrouz, 2015, Cloning, expression and purification of Pseudomonas aeruginosa flagellin and characterization of elicited anti-flagellin antibody, Iran Red Crescent Med J Asadi Karam, 2013, Vaccination with recombinant FimH fused with flagellin enhances cellular and humoral immunity against urinary tract infection in mice, Vaccine, 31, 1210, 10.1016/j.vaccine.2012.12.059 Neely, 1999, Then and now: studies using a burned mouse model reflect trends in burn research over the past 25 years, Burns, 25, 603, 10.1016/S0305-4179(99)00068-6 Ames, 1985, Opsonophagocytic killing activity of rabbit antibody to Pseudomonas aeruginosa mucoid exopolysaccharide, Infect Immun, 49, 281, 10.1128/IAI.49.2.281-285.1985 Ray, 2010, Isolation of mouse peritoneal cavity cells, J Vis Exp, 10.3791/1488 Brett, 1994, Isolation and characterization of Pseudomonas pseudomallei flagellin proteins, Infect Immun, 62, 1914, 10.1128/IAI.62.5.1914-1919.1994 Johansen, 2013, Vaccines for preventing infection with Pseudomonas aeruginosa in cystic fibrosis, Cochrane Database Syst Rev, 6, 10.1002/14651858.CD001399.pub3 Backhed, 2003, Structural requirements for TLR4-mediated LPS signalling: a biological role for LPS modifications, Microbes Infect, 5, 1057, 10.1016/S1286-4579(03)00207-7 Crowe, 1991, The first clinical trial of immuno's experimental Pseudomonas aeruginosa flagellar vaccines, Antibiot Chemother, 44, 143, 10.1159/000420309 Tang, 2011, Lack of peripheral memory B cell responses in recovered patients with severe acute respiratory syndrome: a six-year follow-up study, J Immunol, 186, 7264, 10.4049/jimmunol.0903490 Didierlaurent, 2004, Flagellin promotes myeloid differentiation factor 88-dependent development of Th2-type response, J Immunol, 172, 6922, 10.4049/jimmunol.172.11.6922 Means, 2003, The Toll-like receptor 5 stimulus bacterial flagellin induces maturation and chemokine production in human dendritic cells, J Immunol, 170, 5165, 10.4049/jimmunol.170.10.5165 Stavnezer, 2008, Mechanism and regulation of class switch recombination, Annu Rev Immunol, 26, 261, 10.1146/annurev.immunol.26.021607.090248 Casadevall, 2006, A reappraisal of humoral immunity based on mechanisms of antibody-mediated protection against intracellular pathogens, Adv Immunol, 91, 1, 10.1016/S0065-2776(06)91001-3 Hazlett, 2002, The role of Langerhans cells in Pseudomonas aeruginosa infection, Invest Ophthalmol Vis Sci, 43, 189 Kikuchi, 2001, Antigen-pulsed dendritic cells expressing macrophage-derived chemokine elicit Th2 responses and promote specific humoral immunity, J Clin Invest, 108, 917, 10.1172/JCI200111564 Worgall, 2001, Protection against pulmonary infection with Pseudomonas aeruginosa following immunization with P. aeruginosa-pulsed dendritic cells, Infect Immun, 69, 4521, 10.1128/IAI.69.7.4521-4527.2001 Holder, 2001, PcrV immunization enhances survival of burned Pseudomonas aeruginosa-infected mice, Infect Immun, 69, 5908, 10.1128/IAI.69.9.5908-5910.2001 Rendon, 2012, Th17 cells: critical mediators of host responses to burn injury and sepsis, J Leukoc Biol, 92, 529, 10.1189/jlb.0212083 Campodonico, 2010, Evaluation of flagella and flagellin of Pseudomonas aeruginosa as vaccines, Infect Immun, 78, 746, 10.1128/IAI.00806-09 Drake, 1988, Flagella, motility and invasive virulence of Pseudomonas aeruginosa, J Gen Microbiol, 134, 43 Montie, 1982, Flagellar preparations from Pseudomonas aeruginosa: isolation and characterization, Infect Immun, 35, 281, 10.1128/IAI.35.1.281-288.1982 Faezi, 2011, Passive immunisation against Pseudomonas aeruginosa recombinant flagellin in an experimental model of burn wound sepsis, Burns, 37, 865, 10.1016/j.burns.2010.12.003 Sabharwal, 2014, New possibility for providing protection against urinary tract infection caused by Pseudomonas aeruginosa by non-adjuvanted flagellin ‘b’ induced immunity, Immunol Lett, 162, 229, 10.1016/j.imlet.2014.10.018 Neville, 2005, Antibodies raised against N′-terminal Pseudomonas aeruginosa flagellin prevent mortality in lethal murine models of infection, Int J Mol Med, 16, 165 Ben-Yedidia, 1999, Intranasal administration of peptide vaccine protects human/mouse radiation chimera from influenza infection, Int Immunol, 11, 1043, 10.1093/intimm/11.7.1043 Honko, 2004, Mucosal administration of flagellin induces innate immunity in the mouse lung, Infect Immun, 72, 6676, 10.1128/IAI.72.11.6676-6679.2004 Barnea, 2009, Therapy with anti-flagellin A monoclonal antibody limits Pseudomonas aeruginosa invasiveness in a mouse burn wound sepsis model, Burns, 35, 390, 10.1016/j.burns.2008.08.014